8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
|
|
- CAS-Nr.
- 853029-57-9
- Englisch Name:
- 8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
- Synonyma:
- 8-Bromo-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione;1-[(4-Methylquinazolin-2-yl)Methyl]-3-Methyl-7-(2-butin-1-yl)-8-broMoxanthine;8-bromo-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-1H-purine-2,6-dione;1-[(4-Methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-bromoxanthine;Linaint-H;Linagliptin-1;8-Bromo-7-but;LIP-1A IMPURITY;Linagliptin Impurity 32;Linagliptin Impurity 94
- CBNumber:
- CB72535826
- Summenformel:
- C20H17BrN6O2
- Molgewicht:
- 453.29
- MOL-Datei:
- 853029-57-9.mol
|
8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione Eigenschaften
- Schmelzpunkt:
- >255°C (dec.)
- Siedepunkt:
- 602.9±65.0 °C(Predicted)
- Dichte
- 1.55
- storage temp.
- under inert gas (nitrogen or Argon) at 2-8°C
- Löslichkeit
- DMSO (Slightly, Heated, Sonicated), Methanol (Very Slightly, Heated, Sonicated)
- pka
- 2.34±0.50(Predicted)
- Aggregatzustand
- Solid
- Farbe
- White to Pale Yellow
Sicherheit
8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione Chemische Eigenschaften,Einsatz,Produktion Methoden
8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 274)Lieferanten
- 8-BroMo-7-(2-butyn-a-yl)-3,7-dihydro-3-Methyl-1-[(4-Methyl-2-quinazolinyl)Methyl]-1H-purine-2,6-dione
- 8-Bromo-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquin-azolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dion
- 8-BroMo-7-(but-2-yn-1-yl)-3-Methyl-1-((4-Methylquinazolin-2-yl)Methyl)-1H-purine-2,6(3H,7H)-dione
- 1H-Purine-2,6-dione,8-broMo-7-(2-butynyl)-3,7-dihydro-3-Methyl-1-[(4-Methyl-2-quinazolinyl)Methyl]-
- Linagliptin interMediate F
- 1H-Purine-2,6-dione, 8-bromo-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-
- Iinagliptin Intermediate3
- 8-Bromo-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquin-azolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-d
- 8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione
- 8-BroMo-7-but-2-ynyl-3-Methyl-1-(4-Methyquinazolin-2-ylMethyl)-3,7-dihydro-purine-2,6-dione
- 8-broMo-7-(but-2-ynyl)-3-Methyl-1-((4-Methylquinazolin-2-yl)Methyl)-1H-purine-2,6(3H,7H)-dione
- 8-bromo-7-but-2-ynyl-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]purine-2,6-dione
- Linagliptinmothernucleus
- Linaint-H
- Linagliptin Impurity 32
- 8-bromo-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione
- Linagliptin-1
- 8-bromo-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)
- 8-bromo-7-(2-butyne)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-xanthine
- Linagliptin IntermediateLinagliptin Intermediate
- 8-BROMO-7-BUT-2-YNYL-3-METHYL-1-(4-METHYL-QUINAZOLIN-2-YLMETHYL)-3,7-DIHYDRO-PURINE-2,6-DIONE 853029-57-9
- 8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione ISO 9001:2015 REACH
- (2-(chloromethyl)-4-methylquinazoline),8-Bromo-7-but-2-ynyl-3-methyl-1-(4- methyl-quinazolin-2-ylmethyl)-3,7- dihydro-purine-2,6-dione
- Linagliptin Impurity 94
- 1-[(4-methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl...
- 1-[(4-Methylquinazolin-2-yl)Methyl]-3-Methyl-7-(2-butin-1-yl)-8-broMoxanthine
- 8-bromo-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-1H-purine-2,6-dione
- 1-[(4-Methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-bromoxanthine
- 8-Bromo-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dione
- 8-Bromo-7-(2-Butyn-1-Yl)-3,7-Dihydro-3-Methyl-1-[(4-Methyl-2-Quinazolinyl)Methyl]-1H-Purine-2,6-Dione / Linagliptin Intermediate
- 1H-Imidazole-4-carboxaldehyde,8-methyl-
- 8- bromo -7-(2- butyn -1- yl) -3,7- dihydro -3- methyl -1-[(4- methyl -2- quinazolinyl) methyl ]-1H- purin -2,6- dione
- 1-[(4-Methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl) 8-bromoyanthine
- 8-brom-7- (2-butynyl-1-yl) -3,7-dihydro-3-methyl-1- [(4-methyl-2-quinazolino) methyl] -1H-purine-2,6-dione
- Linagliptin intermediate 1-[(4-methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-bromoxanthine
- 8-Bromo-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H-purine-2,6-dion
- Linagliptin Related Compound-11 (Bromo compound)
- 8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-xanthine
- 8-Bromo-7-but
- LIP-1A IMPURITY
- 853029-57-9
- C20H17BrN6O2
- Intermediates
- 853029-57-9